Cart
sales@molnova.com
Parethoxycaine hydrochloride
CAS No. 136-46-9
Parethoxycaine hydrochloride( 2-(diethylamino)ethyl 4-ethoxybenzoate hydrochloride | Diethoxin )
Catalog No. M28658 CAS No. 136-46-9
Parethoxycaine hydrochloride is an anesthetic.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 187 | In Stock |
|
| 5MG | 192 | In Stock |
|
| 10MG | 281 | In Stock |
|
| 25MG | 449 | In Stock |
|
| 50MG | 625 | In Stock |
|
| 100MG | 830 | In Stock |
|
| 200MG | 1097 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameParethoxycaine hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionParethoxycaine hydrochloride is an anesthetic.
-
DescriptionParethoxycaine hydrochloride is an anesthetic.
-
In Vitro——
-
In Vivo——
-
Synonyms2-(diethylamino)ethyl 4-ethoxybenzoate hydrochloride | Diethoxin
-
PathwayOthers
-
TargetOther Targets
-
RecptorTyrosine phosphatase|c-Src
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number136-46-9
-
Formula Weight301.81
-
Molecular FormulaC15H24ClNO3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCCN(CC)CCOC(c(cc1)ccc1OCC)=O.Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Ku B, et al. Identification of N-(5-(phenoxymethyl)-1,3,4-thiadiazol-2-yl)acetamide derivatives as novel protein tyrosine phosphatase epsilon inhibitors exhibiting anti-osteoclastic activity. ioorg Med Chem. 2018 Oct 1;26(18):5204-5211.
molnova catalog
related products
-
Yuanhuanin
Yuanhuanin is a natural product for research related to life sciences.
-
Netupitant
Netupitant is a specific neurokinin 1 (NK1) receptor antagonist (Ki: 0.95 nM).
-
Oxindole
Oxindole is an aromatic heterocyclic building block.?2-indolinone derivatives have become lead compounds in the research of kinase inhibitors.Oxindole structure has been used in receptor tyrosine kinases (RTKs) inhibitors such as SU4984 and intedanib, the RTK family represents an important therapeutic target for anti-cancer drug development.
